Enzene, a leading global continuously innovative development and manufacturing organisation (CIDMO), welcomes the news that its EnzeneX 2.0 platform, featuring fully connected continuous manufacturing (FCCM) technology, won the 2025 CPHI Pharma Award for Manufacturing Excellence.
The award recognises innovation in technologies, processes and services for the manufacture of various dose forms.
And, as the first truly fully connected continuous manufacturing technology to be validated for commercial biologics supply, the award acknowledged the EnzeneX 2.0 platform for advancing bioprocessing.
“I am delighted to accept this award on behalf of Enzene,” commented Himanshu Gadgil, PhD, CEO of Enzene.
“By taking advantage of the modular design of the EnzeneX platform, and its integrated process controls, innovators have not only validated the FCCM technology for commercial-scale supply, but have also successfully driven down the costs of bioprocessing across a broad range of biologic modalities.”
The winner’s award was presented to Enzene at a ceremony on 28 October 2025 at CPHI Frankfurt, the world’s largest pharmaceutical event, which is currently taking place at Messe Frankfurt.